


Culture kit for activated lymphocytes (CAT)

The Activated Lymphocyte Culture Kit is a kit for convenient culture of activated lymphocytes from canine and feline peripheral blood.



Forte





Minimally invasive with only an intravenous infusion


Leading the way, unparalleled in the U.S. and abroad

Composition


This all-in-one culture kit includes everything necessary for a single treatment from culture to administration, including culture bag, culture medium, and pipettes.

Application Examples

Using our activated lymphocyte culture kit, we cultured canine peripheral blood. In the obtained cultured cells, gene expression levels of IFN- \upsigma , which enhances the ability to attack cancer cells, and proenkephalin, an opioid that exerts analgesic effects, increased 3.5- and 2.7-fold, respectively, compared to those before culture (Figure 1). In addition, when these cultured cells were cultured together with cancer cells, most of the cancer cells were killed (Figure 2). These results indicate that opioid production from the proliferating cells as well as IFN- \upsigma production increased and their ability to kill cancer cells increased.



The CHQLS-15 (Figure 3) reported by Lavan (2013) was used to assess quality of life in 74 tumoraffected dogs treated with activated lymphocyte therapy. The average pre-treatment score was 3.0. The average score before treatment was 3.2, but it increased with each administration, reaching 3.6 at the sixth administration (Figure 4). These results indicate that activated lymphocyte therapy for dogs with tumors improved QOL and that QOL can be



Literature and Presentations

- 1) Mitani K, Ito Y, Takene Y, Hatoya S, Sugiura K, Inaba T. Quality of life-improving effect of autologous ex vivo expanded cytotoxic and opioid-producing lymphocytes for dogs with cancers. Vet. Immunol. Immunopathol. 2021.
- 2) Mitani K, Ito Y, Takene K, Inaba T, Sugiura K. Isolation of opioid-producing cells by canine activated lymphocyte culture kit and analysis of its clinical application results. Japanese Society for Veterinary Regenerative Medicine 15th Annual Meeting 2020.
- 3) Tohya S, Mitani K, Ito Y, Inaba T, Okada K. (J-ARM Inc.), QOL evaluation by owners in canine cancer immunotherapy and fat stem cell therapy, 160th Annual Meeting of the Japanese Society of Veterinary Science 2017.

J-ARM Corporation

5-9-27-201 Abenosuji, Abeno-ku, Osaka-shi, Osaka

TEL&FAX: 06-7890-5959 order@j-arm.com